US 12,005,082 B2
Composition and method of use recombinant fusion protein to generate CAR-immune cells
Youngwook Won, Southlake, TX (US); Seungmin Han, Denton, TX (US); and David Bull, Salt Lake City, UT (US)
Assigned to SINGULAR IMMUNE, INC., Dallas, TX (US)
Filed by SINGULAR IMMUNE, INC., Dallas, TX (US)
Filed on Mar. 17, 2023, as Appl. No. 18/185,805.
Claims priority of provisional application 63/320,885, filed on Mar. 17, 2022.
Prior Publication US 2023/0293584 A1, Sep. 21, 2023
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2827 (2013.01)] 16 Claims
 
1. A recombinant chimeric antigen receptor (CAR) fusion protein comprising, in order:
an immune cell targeting domain, the immune cell targeting domain being a NK cell targeting domain, or a T cell targeting domain,
a cleavable peptide,
a membrane targeting domain, the membrane targeting domain being a peptide from interleukin-1 receptor type 1, 4F2 cell-surface antigen heavy chain, a linker for activation of T-cells family member 1, junctophilin-1, antilisterial bacteriocin subtilosin biosynthesis protein AlbG, calcitonin receptor, gamma-secretase subunit APH-1A, or adipnectin receptor protein 2,
an extracellular cancer targeting domain,
a transmembrane domain, and
an intracellular signaling domain.